RxDoctor Payments DataLook up a doctor →

Ray Smith, MD

Interventional Cardiology · Shreveport, LANPI 1851375349

Payments from drug & device makers

$45,130in general payments, 2019–2025

Across 371 payments — averaging $121.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$21K
  • AstraZeneca$14K
  • Silk Road Medical, Inc.$1K
  • Cardiovascular Systems Inc.$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$585
  • Philips North America LLC$517
  • plus $6K from 35 others

What the payments were for

  • Speaking & faculty fees$1461%
  • Travel & lodging$1,13711%
  • Food & beverage$8,70586%
  • Education$1612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,130 in reported general payments places this provider in the 75th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$654,689
Medicare patients
1,847
Services billed
6,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban489$354,858
EntrestoSacubitril/Valsartan286$244,879
XareltoRivaroxaban206$162,598
JardianceEmpagliflozin113$81,318
FarxigaDapagliflozin Propanediol95$80,089
Repatha SureclickEvolocumab53$43,999
MultaqDronedarone Hcl22$35,518
BrilintaTicagrelor39$23,196
Metoprolol Succinate1,405$14,444
NexlizetBempedoic Acid/Ezetimibe21$8,695
Praluent PenAlirocumab15$7,918
NexletolBempedoic Acid13$5,148
ClopidogrelClopidogrel Bisulfate557$4,674
Ranolazine ErRanolazine59$4,582
Rosuvastatin Calcium354$4,340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$65$354,858489 claims
NovartisEntresto$54$244,879286 claims
Johnson & JohnsonXarelto$344$162,598206 claims
AstraZenecaFarxiga, Brilinta$14,068$103,285134 claims
Boehringer IngelheimJardiance$151$81,318113 claims
Sanofi-aventis U.S. LLCMultaq$55$35,51822 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$58$13,84334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →